Serum GDF 15 Levels Correlate to Mitochondrial Disease Severity and Myocardial Strain , but Not to Disease Progression in Adult m . 3243 A > G Carriers

In this observational cohort study, we examined the prognostic value of growth and differentiation factor 15 (GDF15) in indicating and monitoring general mitochondrial disease severity and progression in adult carriers of the m.3243A>G mutation. Ninety-seven adult carriers of the m.3243A>G mutation were included in this study. The Newcastle mitochondrial disease adult scale was used for rating mitochondrial disease severity. In parallel, blood was drawn for GDF15 analysis by ELISA. Forty-nine carriers were included in a follow-up study. In a small subset of subjects of whom an echocardiogram was available from general patient care, myocardial deformation was assessed using two-dimensional speckle-tracking strain analysis. A moderate positive correlation was found between the concentration of GDF15 and disease severity (r 1⁄4 0.59; p < 0.001). The concentration of serum GDF15 was higher in m.3243A>G carriers with diabetes mellitus, cardiomyopathy, and renal abnormalities. After a 2-year follow-up, no significant correlation was found between the change in disease severity and the change in the concentration of GDF15 or between the GDF15 level at the first assessment and the change in disease severity. In the subcohort of patients of whom an echocardiogram was available, the concentration of GDF15 correlated moderately to longitudinal global strain (r 1⁄4 0.55; p 1⁄4 0.006; n 1⁄4 23) but not to circumferential or radial strain. Our results indicate that serum GDF15 is not a strong surrogate marker for general mitochondrial disease severity. Its value in indicating myocardial deformation should be confirmed in a prospective longitudinal study.

[1]  M. Cerqueira,et al.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2014, European heart journal cardiovascular Imaging.

[2]  A. Domínguez-Rodríguez,et al.  Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus. , 2014, The American journal of cardiology.

[3]  S. Yatsuga,et al.  Growth Differentiation Factor 15 and Fibroblast Growth Factor 21: Novel Biomarkers for Mitochondrial Diseases , 2014 .

[4]  D. Vriens,et al.  Serum FGF21 levels in adult m.3243A>G carriers , 2014, Neurology.

[5]  D. Zhu,et al.  GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  A. Mavinkurve-Groothuis,et al.  Early myocardial deformation abnormalities in breast cancer survivors , 2014, Breast Cancer Research and Treatment.

[7]  Y. Izumiya,et al.  Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. , 2014, The Canadian journal of cardiology.

[8]  F. Amant,et al.  Growth Differentiation Factor-15 as Biomarker in Uterine Sarcomas , 2014, International Journal of Gynecologic Cancer.

[9]  M. G. St. John Sutton,et al.  Longitudinal Strain in Friedreich Ataxia: A Potential Marker for Early Left Ventricular Dysfunction , 2013, Echocardiography.

[10]  L. de Meirleir,et al.  Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies , 2014, BMC Genomics.

[11]  R. Vasan,et al.  Biomarkers of cardiovascular stress and incident chronic kidney disease. , 2013, Clinical chemistry.

[12]  V. Mootha,et al.  New treatments for mitochondrial disease—no time to drop our standards , 2013, Nature Reviews Neurology.

[13]  K. Wollert,et al.  Risk stratification in critically ill patients: GDF-15 scores in adult respiratory distress syndrome , 2013, Critical Care.

[14]  Robert W. Taylor,et al.  Concentric hypertrophic remodelling and subendocardial dysfunction in mitochondrial DNA point mutation carriers† , 2012, European heart journal cardiovascular Imaging.

[15]  Andrew D. Johnson,et al.  Clinical and genetic correlates of growth differentiation factor 15 in the community. , 2012, Clinical chemistry.

[16]  R. Goldschmeding,et al.  Circulating growth differentiation factor‐15 correlates with myocardial fibrosis in patients with non‐ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support , 2012, European journal of heart failure.

[17]  Robert W. Taylor,et al.  Cardiomyopathy is common in patients with the mitochondrial DNA m.3243A>G mutation and correlates with mutation load , 2012, Neuromuscular Disorders.

[18]  R. Rodenburg,et al.  Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A > G mutation , 2012, Journal of Inherited Metabolic Disease.

[19]  F. Marín,et al.  Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. , 2012, European journal of internal medicine.

[20]  J. Carrero,et al.  Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  W. Gao,et al.  Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[22]  E. Bertini,et al.  Renal involvement in mitochondrial cytopathies , 2011, Pediatric Nephrology.

[23]  R. Mayeux Biomarkers: Potential uses and limitations , 2004, NeuroRX.

[24]  A. Suomalainen Biomarkers for mitochondrial respiratory chain disorders , 2011, Journal of Inherited Metabolic Disease.

[25]  H. Kim,et al.  Initial Experiences with Proton MR Spectroscopy in Treatment Monitoring of Mitochondrial Encephalopathy , 2010, Yonsei medical journal.

[26]  D. Turnbull,et al.  Mitochondrial disease in adults: A scale to monitor progression and treatment , 2006, Neurology.

[27]  M. Akizuki,et al.  Renal complications in a patient with A-to-G mutation of mitochondrial DNA at the 3243 position of leucine tRNA. , 2002, Internal medicine.

[28]  W. D. Fairlie,et al.  The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. , 2000, The Journal of clinical endocrinology and metabolism.